Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor Use for Patients With Non-Small-Cell Lung Cancer Who Receive Chemotherapy: An ASCO Quality Training Program Project of the Cleveland Clinic Taussig Cancer Institute [Quality in Action]

Conclusion:
pGCSF was excessively prescribed for patients with NSCLC. Factors contributing to inappropriate use included provider lack of familiarity with guidelines and knowledge with regard to the risk of neutropenic fever for individual chemotherapy regimens, and electronic medical record chemotherapy templates that contain standing GCSF orders. Interventions to address these gaps quickly produced improved compliance with guidelines and led to significant cost savings.

Source: Journal of Oncology Practice - January 12, 2016 Category: Cancer & Oncology Authors: Martin Goodman, L., Moeller, M. B., Azzouqa, A.-G., Guthrie, A. E., Dalby, C. K., Earl, M. A., Cheng, C., Pennell, N. A., Shapiro, M., Velcheti, V., Stevenson, J. P. Tags: Clinical guidelines, Complications of cancer and cancer treatment, Quality, Patient safety, Quality of care, Quality in Action, Quality of Care, Cost of Cancer Care, Growth Factors, Febrile Neutropenia, Adult Medical Oncology, Chemotherapy Source Type: research